Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hikari Araki
TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models
International Journal of Cancer
Cancer Research
Oncology
TAS4464, a Highly Potent and Selective Inhibitor of NEDD8 Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Preclinical Antitumor Activity of BMS-599626, a Pan-Her Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling
Clinical Cancer Research
Cancer Research
Oncology
CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase With Antitumor Activity in Experimental Models of Human Cancers
Molecular Cancer Therapeutics
Cancer Research
Oncology
P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Antitumor Activity of the Polo-Like Kinase Inhibitor, TAK-960, Against Preclinical Models of Colorectal Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase
GSK1070916, a Potent Aurora B/C Kinase Inhibitor With Broad Antitumor Activity in Tissue Culture Cells and Human Tumor Xenograft Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
